Abstract
Introduction Coronavirus disease 2019 (COVID–19) has infected over 22 million individuals worldwide. It remains unclear whether patients with COVID–19 and Rheumatoid Arthritis (RA) experience worse clinical outcomes compared to similar patients with COVID–19 without RA.
Aim The aim of this study is to provide insights on how COVID–19 impacted patients with RA given the nature of the disease and medication used.
Methods RA cases were identified via International Classification of Diseases (ICD) codes and COVID–19 cases by laboratory results in the U.S. based TriNetX network. Patients with COVID–19 and RA were propensity–score matched based on demographics with patients with COVID–19 without RA at a 1:3 ratio. A hospitalized sub-population was defined by procedure codes.
Results We identified 1,014 COVID-19 patients with RA and 3,042 non-RA matches selected from 137,757 patients. The odds of hospitalization (non-RA:23%, RA:24.6%, OR:1.08, 95% CI: 0.88 to 1.33) or mortality (non-RA:5.4%, RA:6%, OR:0.93, 95% CI: 0.65 to 1.34) were not significantly different.
The hospitalized sub-population included 249 patients with COVID-19 and RA and 745 non-RA matches selected from 21,435 patients. The risk of intensive care unit (ICU) admission (non-RA:18.8%, RA:18.1%, OR:0.94, 95% CI: 0.60 to 1.45), and inpatient mortality (non-RA:14.4%, RA:14.5%, OR:0.86, 95% CI: 0.53 to 1.40) were not significantly different.
Conclusion We didn’t find evidence suggesting patients with COVID–19 and RA are more likely to have severe outcomes than patients with COVID–19 without RA.
Key Messages
– Patients with Rheumatoid Arthritis (RA) tend to be older, and often have co-morbidities which could put them at greater risk of severe COVID-19 outcomes.
– This study is one of the largest studies of COVID-19 infected RA populations to date. We did not find increased risk of hospitalization, ICU admission, or mortality among RA patients vs. matched non-RA patients.
– Patients previously exposed to anti-coagulants experienced higher risks of hospitalization and overall mortality. Extra attention is needed for treating such patients.
Competing Interest Statement
All authors on this paper are employed by Genentech, which is a member of the Roche Group.
Funding Statement
This study was funded by Genentech
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Western Institutional Review Board reviewed the use of TrinetX COVID-19 data and has granted a waiver because of its deidentified nature and no human subject involvement.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Competing Interests: All authors on this paper are employed by Genentech, which is a member of the Roche Group.
Funding Info: This study was funded by Genentech.
Ethical approval information: The protocol for this study is in line with the Declaration of Hensinki (2008). The authors conducted secondary research using de-identified data licensed from TriNetX in compliance with 45 CFR 164.514(a)-(c). The data had identifying information removed and was coded in such a way that the data could not be linked back to subjects from whom it was originally collected.
This research utilized the data licensed by TriNetX and described above, does not require IRB or ethics review, as analyses with this data do not meet the definition of “research involving human subjects” as defined within 45 CFR 46.102(f) which stipulates human subjects as living individuals about whom an investigator obtains identifiable private information for research purposes. Neither the provider of the data nor the researchers were able to link the data with identifiable individuals. Consent to participate was not applicable in this retrospective observational study of de-identified data.
Data Sharing Statement: Data may be obtained from a third party and are not publicly available. This study used data provided by the TriNetX (Cambridge, MA) DataWorks network, which includes 41 Healthcare Organizations (HCOs) and 1,016,769 patients across the United States as of 20 August 2020. In order to use these data, Genentech purchased a license from TriNetX.
Patient and Public Involvement: We included the following statement in the main manuscript: “While this study used patient level data from a large electronic medical record database, no patients or members of the public contributed to the design or analysis of this study.”
Data Availability
We are not providing the patient-level data per TriNetX's policy. TriNetX maintains processes and procedures to respond to questions about the data. If editors or reviewers have questions about TriNetX data, TriNetX provides details on the data provenance and/or the necessary access to audit the processes. If the validity of the data is questioned further, TriNetX would make the data available for a third party audit.
